Aileron Therapeutics, an American company specializing in chemoprotection oncology, is making strides in cancer treatment with its cutting-edge drug, ALRN-6924. The drug is currently undergoing several phases of clinical trials, targeting solid tumors, lymphoma, peripheral T-cell lymphoma, acute myeloid leukemia, myelodysplastic syndrome, and small cell lung cancer. In addition, the company is testing combinations of ALRN-6924 with other drugs, including cytarabine and palbociclib. Aileron was formerly known as Renegade Therapeutics before rebranding in 2007. With headquarters in Boston, Massachusetts, the company has been in operation since 2001.